Last updated on August 2019

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

Brief description of study

The purpose of this trial is to investigate if tralokinumab changes the metabolism of selected CYP substrates in adults with moderate-to-severe AD after:

  • 14 weeks of treatment with tralokinumab
  • a single dose of tralokinumab

Clinical Study Identifier: NCT03556592

Find a site near you

Start Over